Amyloid Plaques Are Surprisingly Dynamic Predicting Recovery

Total Page:16

File Type:pdf, Size:1020Kb

Amyloid Plaques Are Surprisingly Dynamic Predicting Recovery From the publishers of The New England Journal of Medicine July 2008 Vol. 10 No. 7 Amyloid Plaques Are reinforce the notion that amyloid plaques the 40-odor University of Pennsylvania are dynamic, again suggesting that Smell Identification Test (UPSIT) and Surprisingly Dynamic they do not result from an unstoppable an average of 2.9 years later (range, 3 he amyloid hypothesis of Alzheimer march of amyloid accretion but, rather, months to 24 years) with the 40-odor T disease predicts that amyloid plaques from a process wherein plaques may UPSIT or a 12-odor version. (One of the are a precursor of neuronal damage. come and (with manipulation) go. Un- study authors is a shareholder in the However, researchers recently proposed doubtedly, the kinetics are different in company that manufactures the smell that neuronal damage may precede humans, but again, overturning conven- test used.) plaque formation. In this study, the tional wisdom enables the contemplation From baseline to follow-up, 11.3% of authors used a novel imaging technique of therapeutic opportunities that might anosmic and 23.3% of hyposmic patients to provide insights into the chronology heretofore have been discarded out regained their age-adjusted sense of of amyloid deposition in the brains of of hand. smell (although significant improvement transgenic mice bred to overexpress — Sam Gandy, MD, PhD occurred in 56.7% and 42.7%, respec- human amyloid precursor protein. Meyer-Luehmann M et al. Rapid appear- tively). Age, initial severity of smell loss, The authors monitored brain paren- ance and local toxicity of amyloid-β and time from onset to baseline signifi- chyma of these transgenic mice weekly plaques in a mouse model of Alzheimer’s cantly predicted the degree of recovery; disease. Nature 2008 Feb 7; 451:720. and then daily. They observed that fully the cause of initial impairment, elapsed morphologically typical amyloid plaques time between tests, gender, and initial could appear within a single day, and smoking habit did not. The authors em- develop to their final size within 1 week. Predicting Recovery phasize the value of quantitative assess- Evidence of neuritic dystrophy appeared ment of smell loss, as 87 of the study after the plaques appeared. from Smell Loss participants had no smell loss on testing. Comment: his was a longitudinal study of pre- Comment: dictors of recovery in 542 people The development of methods for visual- T Smell identification was undertaken who complained of smell loss due to izing amyloid plaques in vivo has led to by two different methods. The authors various causes, including trauma, infec- ongoing revision of our understanding acknowledge the possibility, but con- tion, surgery, and medical treatments. of the biology of these structures. The sider it unlikely, that the loss of sensitiv- Testing was conducted at baseline (mean first surprise, from 3 years ago, was that ity inherent in comparing the two time since smell loss, 1.08 years) with antibodies against amyloid-β could clear away both deposits and the accompany- ing neuritic dystrophy in mice (Nat Med TABLE OF CONTENTS 2001; 7:369). This was quite unexpected, because experimental solubilization of Amyloid Plaques Are New Brain Tumor Therapies, deposits has required denaturing con- Surprisingly Dynamic ........................49 New Recurrence Patterns ................. 53 centrations of guanidine. The relevance Predicting Recovery from Smell Loss .... 49 SOX1 Antibodies and Paraneoplastic Lambert-Eaton of rapid plaque turnover in mice to Does the Vitamin D Emperor Have Clothes? ..................... 50 Myasthenic Syndrome ....................... 53 what is certainly a slower process in Cortical Demyelination in MS Distinguishing Polymyositis humans remains unclear. But upending and Progressive Multifocal from Inclusion Body Myositis ............54 the conventional wisdom led many in Leukoencephalopathy ........................51 Restless Legs Syndrome Is Associated the field to contemplate amyloid clear- Epilepsy and Mental Retardation with Cardiovascular Disease .............54 ance as a serious therapeutic possibility. in Females: Unusual Inheritance ........51 Diaphragm Shrinkage in Mechanically The current findings indicate that Effects of Vagus Nerve Stimulation Ventilated Patients .............................55 plaque deposition can occur just as on Cardiovascular Regulation ........... 52 Predicting Outcome in Vestibular Neuritis ......................... 55 rapidly as can plaque clearance. This Platelet Aggregometry as a Marker of Risk for Vascular Events: Not Yet ......52 Surgery Beneficial study has become an instant classic, Venous Sinus Stenting for Idiopathic for Lumbar Spinal Stenosis ................56 nicknamed the “popcorn plaque” paper Intracranial Hypertension .................52 among the cognoscenti. The findings Journal Watch (and its design) is a registered trademark of the Massachusetts Medical Society. An editorially independent literature-surveillance newsletter summarizing articles from major medical journals. ©2008 Massachusetts Medical Society. All rights reserved. Disclosure information about our authors can be found at http://neurology.jwatch.org/misc/board_disclosures.dtl Page 50 JOURNAL WATCH NEUROLOGY Volume 10 Number 7 EDITOR-IN-CHIEF different procedures weakens the over- other clinical chemistry assays in the Martin A. Samuels, MD, FAAN, MACP, DSc (hon) all conclusion; if so, the 12-odor test 23 patients with MS and in 23 healthy Professor of Neurology, Harvard Medical School; should have been used on both occasions. laboratory workers (controls). Neurologist-in-Chief and Chairman, Department of Neurology, Although the analysis suggests that The authors state that half of all par- Brigham and Women’s Hospital, Boston original etiology is unimportant, there ticipants had S-25(OH)D levels at or were just two major initial causes (upper below 37 nmol/L (considered deficient) DEPUTY EDITOR respiratory infection and head trauma). at some point during the year. Levels Galen V. Henderson, MD Neurologist, Division of Cerebrovascular Diseases, Idiopathic cases would be difficult to of 25(OH)D were lower and levels of Department of Neurology, include in an etiology-based analysis. intact parathyroid hormone (iPTH) were Brigham and Women’s Hospital, Boston The findings are still useful, but arguably higher during relapses than during re- EXECUTIVE EDITOR they cannot be applied to all cases of missions. The abstract also states, “All Christine Sadlowski smell loss. Intuitively, it would be re- 21 relapses during the study occurred Massachusetts Medical Society markable if all causes of anosmia had at serum iPTH levels >20 ng/L. where- ADVISORY BOARD the same outlook when matched for as 38% of patients in remission had Clive Hawkins, MD, DM initial severity. Given that improvements iPTH levels ≤20 ng/L. There is an in- Professor of Clinical Neurology, Keele University Medical School; University Hospital of North in smell can occur in as little as 3 months, verse relationship between serum vita- Staffordshire, Stoke-on-Trent, United Kingdom the long intervals between the initial min D level and MS clinical activity.” smell loss and baseline for most study Bryan M. Kies, MD Comment: Associate Professor, Neurology Division, Faculty of participants might explain the apparent Health Sciences, University of Cape Town; Senior prognostic similarity for the different This simple clinician had some difficulty Specialist, Groote Schuur Hospital, Cape Town, following the authors’ presentation. The South Africa etiologies. The patients who improved after baseline might have been those who supplementary figure published online Jun Kimura, MD plotted vitamin D levels and relapses Professor, Emeritus, Kyoto University, Kyoto, were tested earlier in their condition’s Japan; Professor, Department of Neurology, evolution than those who fared badly. over a 1-year interval for 12 patients. Iowa University Health Care, Iowa City, IA This is the largest study of smell re- Relapses did not occur any more often Edward H. Koo, MD covery so far and provides guidance during the presumed high-risk months Professor, Department of Neurosciences, (8 in December through May, when University of California at San Diego, La Jolla, CA in a hitherto poorly defined area. The findings are clearly valuable in counsel- vitamin D levels are lowest) than during Alberto Portera-Sanchez, MD the other months (11 relapses). Professor of Neurology, Emeritus, ing patients and plaintiffs in lawsuits. Complutense University, Madrid, Spain They counter the widely held belief that Figure 2 of the article is a scatter plot of S-25(OH)D and iPTH levels from Amy A. Pruitt, MD olfactory loss is largely irreversible and Department of Neurology, University of are consistent with the theory that origi- patient specimens drawn during relapse Pennsylvania Medical Center, Philadelphia nal cause determines outlook. These (21) or remission (122). All values for Thomas D. Sabin, MD results are of value in assessing olfactory the relapses fit well within calculable Professor and Vice Chair, confidence intervals for the remission Department of Neurology, Tufts University disturbance due to trauma and infection. School of Medicine, Boston I suspect the prognosis estimate will values: Mean vitamin D levels and standard deviations (SDs) were Thomas R. Swift, MD be less accurate for anosmia related to Professor and former Chair, Department of Neurology, neurosurgical and neurodegenerative 47.4±14.4 nmol/L
Recommended publications
  • Brain Scan-Blood Test Panel Promises Improved Diagnosis Of
    Medical Center 130 W. Kingsbridge Rd Bronx, NY 10468 (718) 741-4273 Fax (718) 741-4269 Department of Veterans Affairs Health Headlines For Immediate Release February 28, 2020 Sam Gandy, MD, PhD Gregory Elder, MD Brain Scan-Blood Test Panel Promises Improved Diagnosis of Brain Trauma Following Battlefield Blast Exposure New brain scans and blood tests move researchers towards more sensitive diagnosis of battlefield brain trauma and evaluation of new drugs BRONX, NY – An array of tests that combines functional assessment with blood tests and brain scans promises more sensitive and objective estimation of brain degeneration in human veterans exposed to battlefield improvised explosive device (IED) blasts, according to research led by doctors at the Icahn School of Medicine at Mount Sinai and the James J. Peters VA Medical Center. The study was published in Molecular Psychiatry on Tuesday, February 25, and featured on the journal’s cover. Traumatic brain injury (TBI) is associated with acute brain destruction at the time of the injury and is also a risk factor for developing neurodegenerative diseases later in life. It is estimated that 10 to 20 percent of veterans returning from the conflicts in Iraq and Afghanistan sustained mild TBI resulting from IED and other blast exposures. The true prevalence may be even higher, given that many blast- related injuries go undocumented. Symptoms of mild TBI frequently resolve in days to months following injury, but in a subset of patients, symptoms persist and evolve into a chronic syndrome. Veterans who had sustained TBIs may suffer subtle, yet important, endocrine and neuropsychiatric dysfunction.
    [Show full text]
  • Transcriptionist
    00001 1 2 3 4 5 6 7 8 9 10 11 CENTERS FOR MEDICARE AND MEDICAID SERVICES 12 Medicare Evidence Development & Coverage 13 Advisory Committee 14 15 16 17 18 19 20 January 30, 2013 21 22 Centers for Medicare and Medicaid Services 23 7500 Security Boulevard 24 Baltimore, Maryland 25 00002 1 Panelists 2 Chairperson Rita Redberg, MD, MS 3 Vice-Chair 4 Art Sedrakyan, MD, PhD 5 Voting Members Jeffrey W. Cozzens, MD, FACS 6 Raymond E. Faught, Jr., MD A. Mark Fendrick, MD 7 Steven Gutman, MD Paula E. Hartman-Stein, PhD 8 Susan A. Levine, DVM, MS, PhD Theresa Miskimen, MD 9 Curtis Mock, MD, MBA Jerrold Rosenbaum, MD 10 Amy E. Sanders, MD, MS Robert K. Zeman, MD 11 CMS Liaison 12 Louis Jacques, MD 13 Industry Representative Brian Seal, RPh, MBA, PhD 14 Guest Panel Members 15 Peter Herscovitch, MD file:///F|/MEDCAC/PG013013-summation.txt[03/05/2013 7:18:14 AM] Constantine G. Lyketsos, MD, MHS 16 Invited Guest Speakers 17 Paul Aisen, MD Randall J. Bateman, MD 18 Mark Mintun, PhD Steven D. Pearson, MD, MSc, FRCP 19 William Thies, MD 20 Executive Secretary Maria Ellis 21 22 23 24 25 00003 1 TABLE OF CONTENTS 2 Page 3 Opening Remarks Maria Ellis/Louis Jacques, MD/ 4 Rita Redberg, MD 4 5 Introduction of Panel 7 6 CMS Presentation and Presentation of Voting Questions 7 Joseph Hutter, MD 10 Brijet Burton Coachman, MPP, MS, PA-C 13 8 Presentations by Invited Guest Speakers 9 Paul Aisen, MD 15 Randall Bateman, MD 32 10 Steven Pearson, MD, MSc 47 William Thies, MD 69 11 Mark Mintun, MD 82 12 Scheduled Public Comments Stephen Salloway, MD, MS 101 13 Howard Fillit, MD 106 Norman L.
    [Show full text]
  • Departments of Neurology and Neurosurgery
    FEATURED STORY Studying Fluorescence- Guided Surgery www.mountsinai.org See Page 3 SPECIALTY REPORT | WINTER 2017 Departments of Neurology and Neurosurgery IN THIS ISSUE 2 Message From the Chairs 2 Treating Seizure Disorders 3 Studying Fluorescence-Guided Surgery 4 Integrated Neurosurgical Tools, 3D Printing 6 Studying a New Imaging Agent 7 Advancing Intracerebral Hemorrhage Care (Top) Intraoperative detection of residual tumor at the glioblastoma margin with protoporphyrin IX (PPIX) fluorescence during 5-ALA fluorescence- guided surgery. (Bottom) MRI neuronavigation confirms that the location of the tumor fluorescence is outside the gadolinium contrast-enhancing border. MESSAGE FROM THE CHAIRS Treating Seizure Disorders Combining the Minimally Invasive Stereo-EEG Technique With Awake Language Mapping The patient is a 15-year-old right-handed young man, diagnosed at age six in his home country with a le temporoparietal and insular dysembryoplastic neuroepithelial tumor (DNET). The tumor was diagnosed aer the patient presented with seizures consisting of liing his right hand above his head and lauhing for a few seconds. These seizures occurred approximately every 10 days. His other seizure type consisted of a sensation of an electrical current traveling up through his le leg, which frequently resulted in falls Barbara G. Vickrey, MD, MPH that caused multiple so-tissue injuries. He was deemed to have Joshua B. Bederson, MD gelastic as well as focal seizures without loss of consciousness. Over the years, in his home country, he tried 15 anti-seizure Mount Sinai continues to use the most advanced technology medications and underwent placement of a vagus nerve stimulator to make a lasting, global impact on patient care, research, implant—without benefit.
    [Show full text]
  • Mount Sinai Leads Global Program Using Stem Cells, Collaborates with the New York Stem Cell Foundation to Accelerate Cures for Alzheimer’S Disease
    FOR IMMEDIATE RELEASE Contact: Contact: Mount Sinai Press Office David McKeon 212-241-9200 212-365-7440 [email protected] [email protected] Mount Sinai Leads Global Program Using Stem Cells, Collaborates with The New York Stem Cell Foundation to Accelerate Cures for Alzheimer’s Disease Researchers Using Skin Samples and Brain Imaging to Identify Causes and Cures (New York—March 26, 2013) —Sam Gandy, MD, PhD, of the Icahn School of Medicine at Mount Sinai is leading an international team of researchers working to reprogram skin cells into brain cells to gain a better understanding of Alzheimer’s disease (AD). As part of the Consortium, Dr. Gandy is collaborating with Scott Noggle, PhD, the NYSCF – Charles Evans Senior Research Fellow for Alzheimer’s Disease and Director of the New York Stem Cell Foundation (NYSCF)’s laboratory in Manhattan. Dr. Gandy heads the Stem Cell Research Consortium funded by the Cure Alzheimer’s Fund (CAF). The Consortium consists of six institutions that plan to directly investigate, for the first time, brain cells in petri dishes from individual patients who have the common form of AD. Dr. Gandy is working with Dr. Noggle’s team to reprogram skin cells from AD patients into brain cells using stem-cell technology. The research team will obtain and monitor adult AD brain cells, providing not only a way to study the causes of the disease but also a system for discovering potentially effective drugs. The strategy has been nicknamed “the patient- specific disease in a dish” and enables studies on a time scale of minutes or hours, compared with mouse model testing, which routinely requires nine months to one year.
    [Show full text]
  • B87118dcd374d4040914d63600
    F1000Research 2017, 6:413 Last updated: 19 APR 2017 OPINION ARTICLE Midlife interventions are critical in prevention, delay, or improvement of Alzheimer’s disease and vascular cognitive impairment and dementia [version 1; referees: 2 approved] Sam Gandy 1,2, Tamas Bartfai3, Graham V. Lees4, Mary Sano2 1Department of Neurology and NFL Neurological Center, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA 2Department of Psychiatry and Alzheimer’s Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA 3Department of Neurochemistry, Stockholm University, Stockholm, 114 18, Sweden 4Corpus Alienum Oy, Kirkkonummi, 02400, Finland v1 First published: 03 Apr 2017, 6:413 (doi: 10.12688/f1000research.11140.1) Open Peer Review Latest published: 03 Apr 2017, 6:413 (doi: 10.12688/f1000research.11140.1) Referee Status: Abstract The basic strategy for focusing exclusively on genetically identified targets for intervening in late life dementias was formulated 30 years ago. Three decades Invited Referees and billions of dollars later, all efforts at disease-modifying interventions have 1 2 failed. Over that same period, evidence has accrued pointing to dementias as late-life clinical phenotypes that begin as midlife pathologies. Effective version 1 prevention therefore may need to begin in midlife, in order to succeed. No published report report current interventions are sufficiently safe to justify their use in midlife dementia 03 Apr 2017 prevention trials. Observational studies could be informative in testing the proposal that amyloid imaging and APOEε4 genotype can predict those who W.Sue T Griffin, University of Arkansas for are highly likely to develop Alzheimer’s disease and in whom higher risk 1 interventions might be justifiable.
    [Show full text]
  • A Workshop on Cognitive Aging and Impairment in the 9/11-Exposed Population
    International Journal of Environmental Research and Public Health Review A Workshop on Cognitive Aging and Impairment in the 9/11-Exposed Population Robert D. Daniels 1,* , Sean A. P. Clouston 2 , Charles B. Hall 3 , Kristi R. Anderson 1 , David A. Bennett 4, Evelyn J. Bromet 2, Geoffrey M. Calvert 1, Tania Carreón 1 , Steven T. DeKosky 5, Erica D. Diminich 2, Caleb E. Finch 6, Sam Gandy 7, William C. Kreisl 8, Minos Kritikos 2 , Travis L. Kubale 1, Michelle M. Mielke 9 , Elaine R. Peskind 10, Murray A. Raskind 11, Marcus Richards 12, Mary Sano 7, Albeliz Santiago-Colón 1 , Richard P. Sloan 13, Avron Spiro III 14 , Neil Vasdev 15 , Benjamin J. Luft 2 and Dori B. Reissman 1 1 World Trade Center Health Program, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Washington, DC 20201, USA; [email protected] (K.R.A.); [email protected] (G.M.C.); [email protected] (T.C.); [email protected] (T.L.K.); [email protected] (A.S.-C.); [email protected] (D.B.R.) 2 Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; [email protected] (S.A.P.C.); [email protected] (E.J.B.); [email protected] (E.D.D.); [email protected] (M.K.); [email protected] (B.J.L.) 3 Department of Epidemiology & Population Health (Biostatistics), Albert Einstein College of Medicine, Bronx, NY 10461, USA; [email protected] 4 Department of Neurological Sciences, Rush Medical College, Rush University, Chicago, IL 60612,
    [Show full text]
  • Relationship of Traumatic Brain Injury to Chronic Mental Health Problems and Dementia in Military Veterans
    Accepted Manuscript Title: Relationship of traumatic brain injury to chronic mental health problems and dementia in military veterans Authors: Gregory A. Elder, Michelle E. Ehrlich, Sam Gandy PII: S0304-3940(19)30367-2 DOI: https://doi.org/10.1016/j.neulet.2019.134294 Article Number: 134294 Reference: NSL 134294 To appear in: Neuroscience Letters Received date: 22 February 2019 Revised date: 25 April 2019 Accepted date: 24 May 2019 Please cite this article as: Elder GA, Ehrlich ME, Gandy S, Relationship of traumatic brain injury to chronic mental health problems and dementia in military veterans, Neuroscience Letters (2019), https://doi.org/10.1016/j.neulet.2019.134294 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Relationship of traumatic brain injury to chronic mental health problems and dementia in military veterans Gregory A. Eldera,b,c,d, Michelle E. Ehrlichb,d,f, and Sam Gandyb,c,d,e,g aNeurology Service, James J. Peters Department of Veterans Affairs Medical Center, 130 West Kingsbridge Road, Bronx, New York 10468, USA bDepartment of Neurology, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, New York, New York 10029, USA cDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, New York, New York 10029, USA dMount Sinai Alzheimer’s Disease Research Center and the Ronald M.
    [Show full text]
  • NYSCF PR 2014-01-08 Alzheimers PLOS
    Contact: David McKeon Contact: Mount Sinai Press Office 212-365-7440 212-241-9200 [email protected] [email protected] STEM CELL RESEARCH IDENTIFIES NEW GENE TARGETS IN PATIENTS WITH EARLY-ONSET ALZHEIMER’S DISEASE Scientists provide new insight into cause of Alzheimer’s disease NEW YORK, NY (January 8, 2014) – Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute in collaboration with scientists at the Icahn School of Medicine at Mount Sinai (ISMMS) successfully generated a stem cell model of familial Alzheimer’s disease (FAD). Using this stem cell model, researchers identified fourteen genes that may be implicated in the disease and one gene in particular that shows the importance that inflammation may play in the brain of Alzheimer’s patients. In this study, published today in PLOS ONE, the team of scientists produced stem cells and neural precursor cells (NPCs), representing early neural progenitor cells that build the brain, from patients with severe early-onset AD with mutations in the Presenilin 1 (PSEN1) gene. These NPCs had elevated Abeta42/Abeta40 ratios, indicating elevation of the form of amyloid found in the brains of Alzheimer’s patients. These levels were greater than those in adult cells that did not have the PSEN1mutation. This elevated ratio showed that these NPCs grown in the petri dish were accurately reflecting the cells in the brains of FAD patients. “Our ability to accurately recapitulate the disease in the petri dish is an important advance for this disease. These genes provide us with new targets to help elucidate the cause of sporadic forms of the disease as well provide targets for the discovery of new drugs,” said Susan L.
    [Show full text]
  • United States District Court Eastern District of Pennsylvania in Re: National Football League Players' Concussion Injury Litig
    Case 2:12-md-02323-AB Document 7070-1 Filed 01/11/17 Page 1 of 55 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA IN RE: NATIONAL FOOTBALL LEAGUE PLAYERS’ CONCUSSION No. 2:12-md-02323-AB INJURY LITIGATION MDL No. 2323 Kevin Turner and Shawn Wooden, Civil Action No. 2:14-cv-00029-AB on behalf of themselves and others similarly situated, Plaintiffs, v. National Football League and NFL Properties, LLC, successor-in-interest to NFL Properties, Inc., Defendants. THIS DOCUMENT RELATES TO: ALL ACTIONS FANECA OBJECTORS’ MEMORANDUM OF LAW IN SUPPORT OF PETITION FOR AN AWARD OF ATTORNEYS’ FEES AND EXPENSES Case 2:12-md-02323-AB Document 7070-1 Filed 01/11/17 Page 2 of 55 TABLE OF CONTENTS Page I. INTRODUCTION ................................................................................................................. 1 II. BACKGROUND ................................................................................................................... 2 III. PROCEDURAL HISTORY .................................................................................................. 5 A. The Precursor Lawsuits and the Initial Settlement ....................................................... 5 B. The Faneca Objectors’ Efforts To Improve the Settlement .......................................... 8 1. The Motion To Intervene ..................................................................................... 8 2. The Opposition to Preliminary Approval ............................................................ 9 3. The Rule 23(f) Petition to
    [Show full text]
  • Effective Anti-Alzheimer Ab Therapy Involves Depletion of Specific Ab Oligomer Subtypes
    Effective anti-Alzheimer Ab therapy involves depletion of specific Ab oligomer subtypes Elysse M. Knight, PhD ABSTRACT Soong Ho Kim, PhD Background: Recent studies have implicated specific assembly subtypes of b-amyloid (Ab)pep- Jessica C. Kottwitz, BS tide, specifically soluble oligomers (soAb) as disease-relevant structures that may underlie mem- Asa Hatami, PhD ory loss in Alzheimer disease. Removing existing soluble and insoluble Ab assemblies is thought to Ricardo Albay, BS be essential for any attempt at stabilizing brain function and slowing cognitive decline in Akinobu Suzuki, PhD Alzheimer disease. IV immunoglobulin (IVIg) therapies have been shown to contain naturally Alex Lublin, PhD occurring polyclonal antibodies that recognize conformational neoepitopes of soluble or insoluble Cristina M. Alberini, PhD Ab assemblies including soAb. These naturally occurring polyclonal antibodies have been sug- William L. Klein, PhD gested to underlie the apparent clinical benefits of IVIg. However, direct evidence linking anti-Ab Paul Szabo, PhD antibodies to the clinical bioactivity of IVIg has been lacking. Norman R. Relkin, MD, Methods: Five-month-old female Dutch APP E693Q mice were treated for 3 months with neat PhD IVIg or with IVIg that had been affinity-depleted over immobilized Ab conformers in 1 of 2 assem- Michelle Ehrlich, MD bly states. Memory was assessed in a battery of tests followed by quantification of brain soAb Charles G. Glabe, PhD levels using standard anti-soAb antibodies. Sam Gandy, MD, PhD John W. Steele, PhD Results: We provide evidence that NU4-type soAb (NU4-soAb) assemblies accumulate in the brains of Dutch APP E693Q mice and are associated with defects in memory, even in the absence of insoluble Ab plaques.
    [Show full text]
  • The Friedman Brain Institute
    Advancing the Understanding New Collaboration Multiplexing of Cognitive Loss and Dementia Collaborative Drives Dementia Alison M. Goate, Immunofluorescence in at Mount Sinai’s Alzheimer’s Programs Science and DPhil, Joins the Neocortex in Severe Disease Research Center Awarded Care Delivery Mount Sinai Alzheimer’s Disease The Friedman SPRING 2015 Brain Institute www.mountsinai.org/fbi Compassionate Care, Pioneering Research Alzheimer’s disease and related dementias are among the top 10 causes of recently established Ronald M. Loeb Center for death and debility in the United States, and the number of deaths attributed Alzheimer’s Disease joins Mount Sinai’s long- standing National Institute on Aging-funded to Alzheimer’s disease is expected to triple by 2050, when it is estimated Alzheimer’s Disease Research Center and our that more than 135 million people worldwide will be afflicted. Center for Cognitive Health in driving efforts to better understand dementing illnesses, Without dramatic improvements in our Institutes of Health provides manyfold fewer developing better ways at diagnosing and ability to treat or prevent these illnesses, dollars for dementia. treating them, and working toward ultimate dementia will likely overwhelm health care cures and preventive measures. budgets worldwide. Still, research into the Mount Sinai is leading efforts to study causes and treatment of these dementias Alzheimer’s disease and other dementias, as Eric J. Nestler, MD, PhD does not receive support commensurate with well as chronic traumatic encephalopathies, Nash Family Professor and Chair, Department of Neuroscience; their devastating impact. For example, when which are caused by repeated traumas—even Director, The Friedman Brain Institute compared to the health and economic costs concussions—resulting in similar syndromes [email protected] of cancer and heart disease, the National with shared pathological mechanisms.
    [Show full text]